PCSK9 Inhibitor: Safe Alternative to Fill the Treatment Gap in Statin-Limited Conditions?
Lipid-lowering therapy is of great importance in reducing the burden of atherosclerotic cardiovascular disease. Statins act as first-line therapy in the current lipid management guidelines. However, statin use is limited in (1) statin-induced adverse events, including statin-associated muscle sympto...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
IMR Press
2022-11-01
|
| Series: | Reviews in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.imrpress.com/journal/RCM/23/11/10.31083/j.rcm2311380 |
| _version_ | 1811216711683145728 |
|---|---|
| author | Ying Xiao Zhengqing Ba Shurui Pang Dong Liu Hao Wang Hanyang Liang Yong Wang Jiansong Yuan |
| author_facet | Ying Xiao Zhengqing Ba Shurui Pang Dong Liu Hao Wang Hanyang Liang Yong Wang Jiansong Yuan |
| author_sort | Ying Xiao |
| collection | DOAJ |
| description | Lipid-lowering therapy is of great importance in reducing the burden of atherosclerotic cardiovascular disease. Statins act as first-line therapy in the current lipid management guidelines. However, statin use is limited in (1) statin-induced adverse events, including statin-associated muscle symptoms, new-onset diabetes mellitus, drug-induced liver injuries, acute kidney injuries, cognitive effects, hemorrhagic strokes, and cataracts; (2) special populations, including pregnant and lactating patients, patients with decompensated cirrhosis, and patients on dialysis; (3) coadministration with statin-interactive drugs, such as anti-human immunodeficiency virus drugs, anti-hepatitis C virus drugs, and immunosuppressive drugs. These considerable statin-limited groups are in urgent need of safer alternative lipid-lowering options. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are attracting widespread attention for their documented safety in general populations and superior lipid-lowering properties. Therefore, questions have been raised whether PCSK9 inhibitors could be a safe alternative in patients who are intolerant to statin therapy. In this review, we discuss the safety of PCSK9 inhibitors in statin-limited conditions. We conclude that PCSK9 inhibitors are a safe alternative lipid-lowering therapy in various statin-limited conditions. Furthermore, we identify several limitations in the current literature and suggest future directions, for the refinement of lipid management regimens. |
| first_indexed | 2024-04-12T06:43:17Z |
| format | Article |
| id | doaj.art-009336318e9a459caec7582ebd054cab |
| institution | Directory Open Access Journal |
| issn | 1530-6550 |
| language | English |
| last_indexed | 2024-04-12T06:43:17Z |
| publishDate | 2022-11-01 |
| publisher | IMR Press |
| record_format | Article |
| series | Reviews in Cardiovascular Medicine |
| spelling | doaj.art-009336318e9a459caec7582ebd054cab2022-12-22T03:43:39ZengIMR PressReviews in Cardiovascular Medicine1530-65502022-11-01231138010.31083/j.rcm2311380S1530-6550(22)00731-1PCSK9 Inhibitor: Safe Alternative to Fill the Treatment Gap in Statin-Limited Conditions?Ying Xiao0Zhengqing Ba1Shurui Pang2Dong Liu3Hao Wang4Hanyang Liang5Yong Wang6Jiansong Yuan7Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, 100037 Beijing, ChinaFuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, 100037 Beijing, ChinaInstitute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, 100730 Beijing, ChinaFuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, 100037 Beijing, ChinaPeking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, 100730 Beijing, ChinaFuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, 100037 Beijing, ChinaFuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, 100037 Beijing, ChinaFuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, 100037 Beijing, ChinaLipid-lowering therapy is of great importance in reducing the burden of atherosclerotic cardiovascular disease. Statins act as first-line therapy in the current lipid management guidelines. However, statin use is limited in (1) statin-induced adverse events, including statin-associated muscle symptoms, new-onset diabetes mellitus, drug-induced liver injuries, acute kidney injuries, cognitive effects, hemorrhagic strokes, and cataracts; (2) special populations, including pregnant and lactating patients, patients with decompensated cirrhosis, and patients on dialysis; (3) coadministration with statin-interactive drugs, such as anti-human immunodeficiency virus drugs, anti-hepatitis C virus drugs, and immunosuppressive drugs. These considerable statin-limited groups are in urgent need of safer alternative lipid-lowering options. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are attracting widespread attention for their documented safety in general populations and superior lipid-lowering properties. Therefore, questions have been raised whether PCSK9 inhibitors could be a safe alternative in patients who are intolerant to statin therapy. In this review, we discuss the safety of PCSK9 inhibitors in statin-limited conditions. We conclude that PCSK9 inhibitors are a safe alternative lipid-lowering therapy in various statin-limited conditions. Furthermore, we identify several limitations in the current literature and suggest future directions, for the refinement of lipid management regimens.https://www.imrpress.com/journal/RCM/23/11/10.31083/j.rcm2311380cardiovascular diseaseanti-pcsk9 antibodyproprotein convertase subtilisin/kexin type 9 inhibitorsstatinadverse effectshypolipidemic therapy |
| spellingShingle | Ying Xiao Zhengqing Ba Shurui Pang Dong Liu Hao Wang Hanyang Liang Yong Wang Jiansong Yuan PCSK9 Inhibitor: Safe Alternative to Fill the Treatment Gap in Statin-Limited Conditions? Reviews in Cardiovascular Medicine cardiovascular disease anti-pcsk9 antibody proprotein convertase subtilisin/kexin type 9 inhibitors statin adverse effects hypolipidemic therapy |
| title | PCSK9 Inhibitor: Safe Alternative to Fill the Treatment Gap in Statin-Limited Conditions? |
| title_full | PCSK9 Inhibitor: Safe Alternative to Fill the Treatment Gap in Statin-Limited Conditions? |
| title_fullStr | PCSK9 Inhibitor: Safe Alternative to Fill the Treatment Gap in Statin-Limited Conditions? |
| title_full_unstemmed | PCSK9 Inhibitor: Safe Alternative to Fill the Treatment Gap in Statin-Limited Conditions? |
| title_short | PCSK9 Inhibitor: Safe Alternative to Fill the Treatment Gap in Statin-Limited Conditions? |
| title_sort | pcsk9 inhibitor safe alternative to fill the treatment gap in statin limited conditions |
| topic | cardiovascular disease anti-pcsk9 antibody proprotein convertase subtilisin/kexin type 9 inhibitors statin adverse effects hypolipidemic therapy |
| url | https://www.imrpress.com/journal/RCM/23/11/10.31083/j.rcm2311380 |
| work_keys_str_mv | AT yingxiao pcsk9inhibitorsafealternativetofillthetreatmentgapinstatinlimitedconditions AT zhengqingba pcsk9inhibitorsafealternativetofillthetreatmentgapinstatinlimitedconditions AT shuruipang pcsk9inhibitorsafealternativetofillthetreatmentgapinstatinlimitedconditions AT dongliu pcsk9inhibitorsafealternativetofillthetreatmentgapinstatinlimitedconditions AT haowang pcsk9inhibitorsafealternativetofillthetreatmentgapinstatinlimitedconditions AT hanyangliang pcsk9inhibitorsafealternativetofillthetreatmentgapinstatinlimitedconditions AT yongwang pcsk9inhibitorsafealternativetofillthetreatmentgapinstatinlimitedconditions AT jiansongyuan pcsk9inhibitorsafealternativetofillthetreatmentgapinstatinlimitedconditions |